Evicenter
P&T meetings

Lirafugratinib (Lyrfigtu)

Previously treated FGFR2 fusion or rearrangement-positive cholangiocarcinoma

Also known as RLY-4008
Regulatory submission
NDA submitted January 2026
Last updated
158 sources

Product information and disease descriptionProduct descriptionProduct information

American hospital formulary service (AHFS), or other drug classification

2 evidence topics · 2 sources

Pharmacologic classification in the prescribing information

“LYRFIGTU is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring a FGFR2 fusion or other rearrangement.” (opens the prescribing information at this quote)

Mechanistic classification: FGFR2-selective irreversible inhibitor

“RLY-4008 is a highly selective, irreversible FGFR2 inhibitor designed to overcome these limitations.” (opens the source at this quote in a new tab)

AHFS classification or ATC code

No evidence found.